Literature DB >> 12007192

Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping.

Batia Stark1, Marta Jeison, Irit Bar-Am, Leticia Glaser-Gabay, Jacques Mardoukh, Drorit Luria, Meora Feinmesser, Yacov Goshen, Jerry Stein, Aya Abramov, Rina Zaizov, Isaac Yaniv.   

Abstract

Molecular studies of advanced-stage neuroblastoma (NBL) have revealed a marked genetic heterogeneity. In addition to MYCN amplification and chromosome 1 short-arm deletions/translocations detected by conventional cytogenetics, application of fluorescence in situ hybridization has disclosed a high prevalence of 17q gain, whereas allelotyping and comparative genomic hybridization techniques also have revealed loss of 11q and of other chromosomal material. Using the recently developed technique of spectral karyotyping (SKY), we sought to refine the cytogenetic information, identify hidden recurrent structural chromosomal abnormalities, and compare them to the molecular findings. Thirteen samples of metaphase spreads from 11 patients with advanced-stage NBL were analyzed by SKY. Most of them were found to have complex karyotypes (more than three changes per metaphase) and complex unbalanced rearrangements. Recurrent aberrations leading to 17q gain, deletion of 1p, MYCN amplification, and loss of 11q appeared in 7, 4, 4, and 5 patients, respectively, in simple and complex karyotypes. Chromosome 3 changes and gain of 1q and 7q appeared in 6, 5, and 4 patients, respectively, in complex karyotypes only, reflecting later changes. A strikingly high prevalence of the unbalanced translocation der(11)t(11;17), leading to concomitant 11q loss and 17q gain in 4 patients, delineated a distinct cytogenetic group, none having 1p deletion and/or MYCN amplification. der(11)t(11;17) was associated with complex karyotypes with changes in chromosomes 3 and 7q. The 17q translocations with partners other than 11q were associated with 1p deletion and/or MYCN amplification. The distinct cytogenetic subgroups identified by SKY confirm and extend the recent molecular observations, and suggest that different genes may interact in the der(11)t(11;17) pathway of NBL development and progression. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12007192     DOI: 10.1002/gcc.10082

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  3 in total

1.  2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

Authors:  Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

2.  Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.

Authors:  Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera
Journal:  Virchows Arch       Date:  2008-06-24       Impact factor: 4.064

3.  Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas.

Authors:  David Gisselsson; Gisela Lundberg; Ingrid Ora; Mattias Höglund
Journal:  J Carcinog       Date:  2007-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.